{"analyses":[{"ciLowerLimit":"15.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"30.6","estimateComment":"Strata adjusted difference based on Cochran-Mantel-Haenszel (CMH) method of weighting.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"DIFFERENCE OF MPR","paramValue":"23.2"},{"ciLowerLimit":"2.48","ciPctValue":"95","ciUpperLimit":"6.49","estimateComment":"Strata adjusted odds ratio using Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"4.01"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"41.9","value":"35.4"},{"groupId":"OG001","lowerLimit":"8.2","upperLimit":"17.0","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"Major pathological response (MPR) rate is defined as the percentage of randomized participants with ≤10% residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 360 mg Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery; then post surgery nivolumab 480 mg Q4W adjuvant treatment for up to 13 cycles (approximately 1 year)","id":"OG000","title":"Nivolumab + SOC Chemotherapy"},{"description":"Placebo Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery, then post-surgery placebo Q4W for up to 13 cycles (approximately 1 year).","id":"OG001","title":"Placebo + SOC Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization up to approximately 44 months","title":"Major Pathological Response (MPR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}